ReviewCancers2022
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Cabergoline Induced Pathological Gambling in an Adolescent with ProlactinomaJournal of clinical research in pediatric endocrinology · 2026Article
- Recurrent nasal bleed as initial presenting complaint: a rare complication of giant prolactinoma in a 39-year-old.Annals of medicine and surgery (2012) · 2026Article
- Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase.Acta pharmacologica Sinica · 2026Article
- Review
- Secondary Loss of Response to Dopamine Receptor Agonists in the Treatment of Macroprolactinoma.Cureus · 2025Article
- Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.Journal of neuro-oncology · 2025Article
- When to embark on surgery for prolactin-secreting pituitary adenoma?Annals of medicine and surgery (2012) · 2025Article
- Double PitNETs: A Case Report and Literature Review.Cancers · 2025Review
- Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway.Frontiers in pharmacology · 2025Article
- Allostatic load index in patients with pituitary tumours: a case control study.Frontiers in endocrinology · 2025Article
- Social support and psychological distress of patients with pituitary adenomas: chain-mediated effects of self-efficacy and rumination.Frontiers in psychology · 2025Article
- Hypopituitarism, Diabetes Insipidus, and Syndrome of Inappropriate Antidiuretic Hormone Secretion after Pituitary Macroadenoma Surgery with Indocyanine Green Dye.Diagnostics (Basel, Switzerland) · 2024Article
- Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.Annals of medicine and surgery (2012) · 2024Review
- The Effect of Prolactin on Gene Expression and the Secretion of Reproductive Hormones in Ewes during the Estrus Cycle.Animals : an open access journal from MDPI · 2024Article
- Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas.Frontiers in surgery · 2024Article
- Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.Reviews on recent clinical trials · 2024Article
- Experience in the Treatment of Male Prolactinomas: A Single-Center, 10-Year Retrospective Study.Neuroendocrinology · 2024Article
- Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Frontiers in endocrinology · 2024Review
- Article
- The Role of Aromatase Inhibitors in Male Prolactinoma.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactinomas comprise 30-50% of all pituitary neuroendocrine tumors, frequently occur in females aged 20 to 50, and cause hypogonadism and infertility. In typical cases, female patients exhibit galactorrhea and amenorrhea due to serum prolactin (PRL) elevation, and patients during pregnancy should be carefully treated. During diagnosis, other causes of hyperprolactinemia must be excluded, and an MRI is useful for detecting pituitary neuroendocrine tumors. For treating prolactinoma, dopamine agonists (DAs) are effective for decreasing PRL levels and shrinking tumor size in most patients. Some DA-resistant cases and the molecular mechanisms of resistance to a DA are partially clarified. The side effects of a DA include cardiac valve alterations and impulse control disorders. Although surgical therapies are invasive, recent analysis shows that long-term remission rates are higher than from medical therapies. The treatments for giant or malignant prolactinomas are challenging, and the combination of medication, surgery, and radiation therapy should be considered. Regarding pathogenesis, somatic SF3B1 mutations were recently identified even though molecular mechanisms in most cases of prolactinoma have not been elucidated. To understand the pathogenesis of prolactinomas, the development of new therapeutic approaches for treatment-resistant patients is expected. This review updates the recent advances in understanding the pathogenesis, diagnosis, and therapy of prolactinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.